<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="997">
  <stage>Registered</stage>
  <submitdate>25/11/2005</submitdate>
  <approvaldate>25/11/2005</approvaldate>
  <nctid>NCT00259376</nctid>
  <trial_identification>
    <studytitle>American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm</studytitle>
    <scientifictitle>American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)</scientifictitle>
    <utrn />
    <trialacronym>ADONIS</trialacronym>
    <secondaryid>SR33589B</secondaryid>
    <secondaryid>EFC4788</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <healthcondition>Atrial Flutter</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dronedarone (SR33589)
Treatment: drugs - placebo

Experimental: Dronedarone 400mg bid - dronedarone 400mg tablets

Experimental: Placebo - matching placebo tablets


Treatment: drugs: Dronedarone (SR33589)
oral administration

Treatment: drugs: placebo
oral administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint of the study is the time from randomisation to first documented AF/AFL recurrence</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>- AF/AFL related symptoms collected at the time of ECG/TTEM recording,</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>- mean ventricular rate during AF/AFL at first recorded AF/AFL recurrence (12-lead ECG or TTEM)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>- time from presumed study drug near steady state defined as D5 midnight to first documented AF/AFL recurrence as indicated by ECG/TTEM recording.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients of either sex aged 21 years or more, in sinus rhythm for at least 1 hour at
             the time of randomisation and with at least one ECG-documented AF/AFL episode in the
             last 3 months.</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  MAIN CRITERIA (non-exhaustive list, see protocol for details):

        Women of childbearing potential without adequate birth control, Pregnant women,
        Breastfeeding women, Congestive heart failure NYHA class III or IV, Conditions which
        increase the risk of severe antiarrhythmic drug side effects, Severe associated conditions.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>629</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2003</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>sanofi-aventis Australia administrative office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus
      rhythm after electrical, pharmacological or spontaneous conversion of atrial
      fibrillation/atrial flutter (AF/AFL).

      To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of
      AF/AFL recurrence.

      To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00259376</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>